Get started
Work

Safety and efficacy of the anti-TROP2 antibody-drug conjugate (ADC) IBI130 in patients (pts) with advanced triple-negative breast cancer (TNBC) and other solid tumors: Results from the phase 1 study.

Year: 2025
Type: conference-abstract
DOI: 10.1200/jco.2025.43.16_suppl.1102
Authors: Fan Wu, Qian Chu, Qin Xu, Fuming Qiu, Jin Yang, Christina Teng, Guohui Han, Xi Shi, Vineet Kwatra, Hongtao Li, Caigang Liu, Yuping Sun, Huihui Li, Fanfan Li, Xiaochen Zhang, Andrew Ohyama Parsonson, Jianyun Nie, Faliang Xu, Hui Zhou, Yongmei Yin
Institutions: Fujian Provincial Cancer Hospital, Tongji Hospital, Huazhong University of Science and Technology, Second Affiliated Hospital of Zhejiang University, Zhejiang University, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an Jiaotong University, Shanxi Provincial Cancer Hospital, First Affiliated Hospital of Fujian Medical University, Shandong Tumor Hospital, First Affiliated Hospital of Bengbu Medical College, China Medical University, Shandong First Medical University, Second Affiliated Hospital of Anhui Medical University, First Affiliated Hospital Zhejiang University, Macquarie University, Chongqing University, Chongqing Cancer Hospital, Innovent Biologics (China), Jiangsu Province Hospital
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W4410805262
Cites:
Cited by: 3
Related to: 10